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BACKGROUND: Nearly half of women treated with aromatase inhibitors (AI) develop AI-associated musculoskeletal
symptoms (AIMSS) such as arthralgias, but to the authors’ knowledge the etiology is unclear. The upper extremities
are frequently affected, especially the wrists, hands, and fingers. AI use may also increase the risk of developing
carpal tunnel syndrome. Tendon sheath fluid and tenosynovial changes have been demonstrated by imaging sympto-
matic patients who were treated with AIs. The authors hypothesized that these abnormalities are correlated with
AIMSS. METHODS: Thirty consecutive patients in whom adjuvant therapy with letrozole or exemestane was initiated
on a prospective clinical trial enrolled in a pilot study evaluating tendon and joint abnormalities at baseline and after
3 months of AI therapy. Patients underwent high-resolution ultrasonography of the wrists bilaterally and completed
the Health Assessment Questionnaire (HAQ) and pain Visual Analog Scale (VAS). AIMSS were defined as an increase
in the HAQ or VAS score during AI therapy that exceeded a predefined cutoff. RESULTS: Twenty-five patients com-
pleted both the baseline and 3-month assessments. During the first 12 months of AI therapy, 15 patients developed
AIMSS, and 13 discontinued therapy because of musculoskeletal symptoms. There was a trend toward an association
between the presence of tendon sheath abnormalities on wrist ultrasound at baseline and the development of AIMSS
(P ¼ .06). CONCLUSIONS: Clinically relevant musculoskeletal symptoms develop in women treated with AIs, leading
to treatment discontinuation in a substantial percentage of these patients. However, in the current study, patient-
reported symptoms were not found to be associated with changes visible on wrist ultrasonography. Cancer
2010;116:4360–7. VC 2010 American Cancer Society.
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Aromatase inhibitors (AI) substantially decrease circulating estrogen concentrations in postmenopausal women via
blockade of aromatase, the enzyme responsible for the conversion of androgens to estrogens. This class of drugs is increas-
ingly used for the adjuvant treatment of postmenopausal women with hormone receptor-positive invasive breast cancer,
in part because of data to support their superiority compared with tamoxifen, a selective estrogen receptor modulator.1-9
Although AIs were reported to be relatively well tolerated in the large prospective randomized clinical trials,4,8,10,11 more
recent studies have demonstrated that up to half of treated patients develop AI-associated musculoskeletal symptoms
(AIMSS) such as arthralgias, joint stiffness, and carpal tunnel syndrome (CTS), which can lead to treatment discontinua-
tion.12-15 A previous study found that symptoms of AIMSS appear, on average, within 3 months of the initiation of AI
therapy.14
To the best of our knowledge, the pathophysiology of AIMSS remains unclear. Previously reported studies using
magnetic resonance imaging (MRI) have demonstrated tenosynovitis in a substantial proportion of patients with severe
wrist symptoms.16 A prospective study of 12 women who were treated with AIs demonstrated a high incidence of
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MRI-detected wrist tenosynovitis after 6 months of AI
therapy, and new abnormalities on imaging studies were
associated with a decrease in grip strength.17 However, in
these studies, associations between the objective findings
and the development of patient-reported musculoskeletal
symptoms were not evaluated.
High-resolution ultrasound is an effective and read-
ily accessible tool that identifies abnormalities of the ten-
don sheath, can quantify changes in the median nerve in
CTS,18 and may be applicable for the evaluation of mus-
culoskeletal changes that occur with AI therapy. The
objective of the current pilot study was to prospectively
evaluate the anatomy of the wrist using serial high-resolu-
tion ultrasonography in women initiating treatment with
AIs as part of their adjuvant breast cancer treatment plan.
We hypothesized that the presence of ultrasound-detected
abnormalities of the wrist before treatment initiation, or
their appearance during AI therapy, may be correlated
with the development of AIMSS.
MATERIALS AND METHODS
Patients
Women who enrolled in the multicenter, prospective,
randomized Exemestane and Letrozole Pharmacogenomics
(ELPh) clinical trial (ClinicalTrials.gov #NCT00228956)
between October 2007 and September 2008 at the Univer-
sity of Michigan Comprehensive Cancer Center were
offered concomitant enrollment in this ultrasound sub-
study. As per the parent study, patients were randomized to
receive exemestane (Aromasin; Pfizer, New York, NY) at a
dose of 25 mg orally daily or letrozole (Femara; Novartis,
East Hanover, NJ) at a dose of 2.5mg orally daily. Key eligi-
bility criteria included female gender, postmenopausal sta-
tus, age 18 years, early stage hormone receptor-positive
breast cancer, and intent to initiate adjuvant therapy with an
AI. No prior AI therapy was permitted. All participants
indicated that surgery, radiotherapy, and chemotherapy for
breast cancer were completed before study enrollment. This
substudy excluded patients with a history of prior significant
wrist injury, wrist surgery, or CTS. The protocol was
approved by the Institutional Review Board, and all enrolled
patients provided written informed consent.
Study Design and Interventions
This prospective study of high-resolution wrist ultraso-
nography was conducted as a substudy of the ELPh trial.
The study design of the ELPh trial has been reported pre-
viously.14 Briefly, patients were evaluated at baseline and
after 1, 3, 6, and 12 months of AI therapy to assess
changes in medical history and concomitant medications,
and to complete symptom questionnaires and the modi-
fied Health Assessment Questionnaire (HAQ),19 which
includes a pain Visual Analog Scale (VAS).
AIMSS were previously reported to develop in the
majority of patients treated with AIs within 3 months of
the initiation of therapy.14 Therefore, all patients in this
substudy also completed the Disabilities of the Arm,
Shoulder, and Hand (DASH) questionnaire20 and under-
went evaluation of the bilateral wrists with high-resolu-
tion ultrasonography using 12 to 17 megahertz linear
transducers (Model iU22; Philips, Bothell, WA) at base-
line and after 3 months of AI therapy.
Definition of AIMSS
In the ELPh trial, AIMSS were defined as meeting 1 of
the following criteria at any point during study participa-
tion: 1) HAQ score increased by >0.4 over the baseline
score; 2) pain VAS score 5 cm (of 10-cm VAS) for
patients with no pain (VAS of 0) at baseline; and 3) the
pain VAS score increased and the pain was rated as much
worse or very much worse on a self-rated clinical global
impression scale (graded as 6 or 7)21 for patients reporting
pain at baseline (VAS of>0).14
Wrist Ultrasonography
Patients underwent baseline and 3-month bilateral, high-
resolution ultrasound imaging of the wrist. The ultra-
sound examination included static images and video clips,
as well as a written report of imaging findings. Imaging
data included: 1) the presence or absence of fluid (com-
pressible anechoic or hypoechoic distention), hyperemia
on color or power Doppler imaging, or synovitis (non-
compressible, hypoechoic distention) in the volar or
dorsal joint spaces (distal radioulnar, radiocarpal, and
midcarpal); 2) the presence or absence of fluid, hypere-
mia, or synovitis in the flexor or extensor tendon sheaths;
3) the presence or absence of tendinosis (hypoechoic and
enlarged), full-thickness tear (complete discontinuity), or
partial thickness tear (partial anechoic cleft) in the flexor
or extensor tendons; 4) median nerve area (in mm2) mea-
sured at the wrist crease (using circumferential trace) at
the level of the pisiform; and 5) the presence of subcutane-
ous edema (hypoechoic, linear, and branching distended
lymphatics). Images were analyzed in a blinded manner
by an academic musculoskeletal radiologist after all
patients had undergone both evaluations.
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Statistical Analyses
The primary objective of the current study was to estimate
the 1) incidence of tendon sheath, joint space, and tendon
abnormalities; and 2) increase in median nerve cross-
sectional area before and 3 months after the initiation of
AI therapy, and to quantify those changes based on high-
resolution ultrasonography of the wrist. The secondary
objective was to evaluate associations between objective,
ultrasound-detected changes in the median nerve and ten-
don sheaths and treatment-emergent musculoskeletal
symptoms.
For analysis, the ultrasound abnormalities were
grouped into those affecting the tendon, the tendon
sheath, and the joint space. Change in the average median
nerve area before and 3 months after the initiation of AI
therapy was tested using the Student t test for paired data.
Univariate associations between baseline findings and the
development of AIMSS or early treatment discontinua-
tion were tested using chi-square tests. Logistic regression
was used to model the probability of developing AIMSS
or early treatment discontinuation (2 separate models) as
a function of baseline characteristics and changes in VAS,
HAQ, and DASH scores between baseline and 3 months.




Characteristics of the 29 eligible patients are listed in
Table 1. One patient was found to be ineligible for the
parent study because she was not postmenopausal, and
therefore she was excluded from all analyses. Of the 29 eli-
gible patients, 25 underwent repeat evaluation at 3
months. Two patients discontinued AI therapy before the
3-month study visit because of musculoskeletal symp-
toms. One patient developed intolerable aches and pains,
and the other had fatigue, headache, and myalgias. Of the
other 2 patients who did not undergo ultrasonography at
the 3-month time point, 1 had been noncompliant with
study procedures and was taken off study and 1 developed
fatigue, headaches, and an inability to concentrate and
discontinued AI therapy.
Wrist Ultrasonography Findings
Abnormalities on the baseline high-resolution ultrasound
of the wrist were common, especially in the joint recess
(Table 2); a representative finding is shown in Figure 1,
Top. Nearly half of the patients developed new findings
on ultrasound after 3 months of AI therapy, also primarily
located in the joint recess (Table 3) (representative finding






Median age (range), y 61 (47-83) 59 (47-83)
Race/ethnicity Non-Hispanic White 25 (86%) 22 (88%)
Hispanic White 2 (7%) 1 (4%)
Black 1 (3%) 1 (4%)
Asian 1 (3%) 1 (4%)
BMI, kg/m2 <25 9 (31%) 8 (32%)
25-30 4 (14%) 4 (16%)
>30 16 (55%) 13 (52%)
Prior chemotherapy Any 15 (52%) 13 (52%)
Taxane 12 (41%) 11 (44%)
Prior tamoxifen 10 (34%) 9 (36%)
Median HAQ score (range) 0 (0-0.625) 0 (0-0.750) .97
Median VAS score (range) 2.8 (0-8.1) 2.6 (0-5.7) .49
Median DASH score (range) 5.8 (0-44.8) 6.9 (0-55) .95
Patient-reported joint pain None 11 (38%) 7 (28%) .41
Mild 8 (28%) 7 (28%)
Moderate/severe 10 (34%) 11 (44%)
Patient-reported neuropathy None 13 (45%) 16 (64%) .44
Mild 11 (38%) 4 (16%)
Moderate/severe 5 (17%) 5 (20%)
BMI indicates body mass index; HAQ, Health Assessment Questionnaire; VAS, Visual Analog Scale; DASH, Disabilities of
the Arm, Shoulder, and Hand questionnaire.
a Values are given for patient-reported outcomes at baseline and after 3 months of aromatase inhibitor therapy.
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shown in Fig. 1 Bottom). Abnormalities of the tendon
itself were noted only rarely. Change in the mean median
nerve area with 3 months of AI therapy was not statisti-
cally different (10.4  2.2 mm at baseline vs 10.8  2.5
mm at 3 months).
Changes in Patient-Reported Symptoms
After 3 months of AI therapy, 72% of patients reported
joint pain, with 44% of the total study population report-
ing moderate to severe pain (Table 1). Median scores on
the HAQ and VAS for all patients were unchanged
between baseline and 3 months. It is interesting to note
that approximately half of the study patients reported pre-
existing neuropathy, primarily of mild severity, and this
symptom decreased during AI therapy. Because patients
with CTS were excluded from participation, baseline neu-
ropathy symptoms were likely the result of alternate
etiologies.
Patients were followed on AI therapy until treatment
discontinuation or for at least 1 year. Fifteen patients
(51.7% of the eligible cohort) developed AIMSS after a
median of 6.2 months of AI therapy (range, 1.2-18.6
months). Thirteen patients (44.8% of eligible cohort) dis-
continued AI therapy because of musculoskeletal symp-
toms after a median duration of 10.7 months of therapy
(range, 0.9-21.2 months). The majority of patients subse-
quently switched to a different AI therapy. One additional
patient discontinued AI therapy after the 3-month time
point because of intractable diarrhea.
Associations Between Baseline Findings and
AIMSS or Early Treatment Discontinuation
On univariate analysis, a higher body mass index (BMI)
was found to be associated with a decreased risk of early
treatment discontinuation (odds ratio [OR] across BMI
groups, 0.16; 95% confidence interval [95% CI], 0.03-
0.84 [P ¼ .03]) (Table 4). There also was a trend toward
prior tamoxifen use and a lower risk of early treatment dis-
continuation (OR, 0.05; 95% CI, 0.002-1.0 [P ¼ .05]).
No other significant associations were noted between
baseline patient characteristics or questionnaire scores and
either the development of AIMSS or early treatment
discontinuation because of musculoskeletal symptoms
(Table 4). There was a trend toward an association
between the presence of tendon sheath abnormalities on
ultrasound at baseline and the subsequent development of













Tendon sheath (flexors) 3 (10.3%) 1 (3.4%) 4 (13.8%) 14 (48.3%)
Fluid 3 (10.3%) 1 (3.4%) 4 (13.8%)
Synovitis 0 0 0
Hyperemia 0 0 0
Tendon sheath (extensors) 6 (20.7%) 5 (17.2%) 11 (37.9%)
Fluid 6 (20.7%) 5 (17.2%) 11 (37.9%)
Synovitis 1 (3.4%) 0 1 (3.4%)
Hyperemia 1 (3.4%) 0 1 (3.4%)
Tendon (flexor þ extensor) 1 (3.4%) 1 (3.4%) 2 (6.9%) 2 (6.9%)
Tendinosis 1 (3.4%) 1 (3.4%) 2 (6.9%)
Partial thickness tear 0 0 0
Full thickness tear 0 0 0
Joint recess (volar) 6 (20.7%) 7 (24.1%) 12 (41.4%) 24 (82.8%)
Fluid 4 (13.8%) 6 (20.7%) 10 (34.5%)
Synovitis 2 (6.9%) 3 (10.3%) 5 (17.2%)
Hyperemia 0 0 0
Joint recess (dorsal) 12 (41.4%) 18 (62.1%) 24 (82.8%)
Fluid 5 (17.2%) 16 (55.2%) 21 (72.4%)
Synovitis 4 (13.8%) 9 (31.0%) 13 (44.8%)
Hyperemia 5 (17.2%) 2 (6.9%) 7 (24.1%)
AI indicates aromatase inhibitor.
a Numbers do not necessarily add up to totals because some patients had >1 abnormality present (eg, both fluid and synovitis of the extensor tendon
sheath).
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AIMSS (Fig. 2 Top). Ten of the 15 patients (67%) who
developed AIMSS during 12 months of AI therapy had
tendon sheath abnormalities at baseline, compared with 4
of 14 patients (29%) who did not develop AIMSS (P ¼
.06). No statistically significant associations between base-
line ultrasound findings and either the development of
AIMSS (Fig. 2 Top) or early treatment discontinuation
(Fig. 2 Bottom) were noted.
Associations Between Changes in Findings
After 3 Months of AI Therapy and AIMSS or
Early Treatment Discontinuation
No associations were noted between changes from base-
line to after 3 months of AI therapy in HAQ, VAS, or
DASH scores and the development of AIMSS or early
treatment discontinuation (Table 4). Similar to the find-
ings at baseline, we did not observe statistically significant
associations between new findings on ultrasonography
and either the development of AIMSS or early treatment
discontinuation (Fig. 3).
Although a previous analysis suggested that the
majority of AI-treated patients develop symptoms within
3 months of treatment initiation, the median time to the
development of AIMSS in the cohort enrolled in the cur-
rent substudy was 6.2 months. Patients enrolled in this
substudy completed the HAQ and VAS questionnaires at
multiple additional time points as part of the parent
study. Therefore, we performed an unplanned analysis of
the correlation between the development of AIMSS and
early treatment discontinuation and changes in the HAQ
and VAS scores from baseline to either 12 months or the
time of early treatment discontinuation, whichever came
first. We found a significant association between changes
in the VAS score and the development of AIMSS (OR,
2.11; 95% CI, 1.1-4.2 [P¼ .03]) and early treatment dis-
continuation (OR, 2.12; 95% CI, 1.1-4.1 [P ¼ .02]). A
similar finding was not noted with changes in the HAQ
score (Table 4).
DISCUSSION
In the current study, abnormalities of the tendon sheath
and joint space at the bilateral wrist detected on high-reso-
lution ultrasound were very common in women before
the initiation of AI therapy. We observed a trend toward
an association between tendon sheath abnormalities on
ultrasonography before treatment initiation and the devel-
opment of AIMSS. The identification of factors predictive
of the increased likelihood of developing AIMSS would
be useful for counseling and managing patients who are
initiating treatment with adjuvant endocrine therapy.
Although this study does not provide new insight into
the mechanism of AIMSS, our results suggest that
pre-existing abnormalities within the tendon sheath may
predict which women are likely to experience AI-associ-
ated musculoskeletal pain.
The findings of the current study are similar to those
of previous reports, the majority of which have been cross-
sectional studies.16,17,22 A strength of the current study
is the prospective, serial assessment of patients using
both high-resolution ultrasound and patient self-report
questionnaires.
A higher than anticipated number of patients dis-
continued therapy because of musculoskeletal symptoms,
possibly because of chance in this small patient cohort, or
possibly because they were enrolled in a clinical trial with
a specific focus on musculoskeletal symptoms, which may
Figure 1. Joint recess and extensor tendon abnormalities are
shown. (Top) Baseline sagittal ultrasound image over the dor-
sal wrist demonstrates hypoechoic fluid distending the
(arrow) dorsal recess of the radiocarpal joint and (arrow-
head) surrounding the extensor tendon. (Bottom) A 3-month
sagittal ultrasound image over the dorsal wrist demonstrates
heterogeneous hypoechoic fluid and synovitis distending the
(arrows) dorsal recesses of the radiocarpal and midcarpal
joints. R indicates radius; t, extensor tendon; L, lunate; C, cap-
itate. The right side of the image is distal.
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have led to greater awareness of toxicity on the part of
both the patient and physician. Similar to other reports,
patients in this cohort who were previously treated with
tamoxifen were less likely to discontinue AI therapy.13
However, contrary to other reports,12,13 there was an asso-
ciation noted between obesity and a decreased risk of













Tendon sheath (flexors) 1 (4%) 0 1 (4%) 5 (20%)
Fluid 1 (4%) 0 1 (4%)
Synovitis 0 0 0
Hyperemia 0 0 0
Tendon sheath (extensors) 4 (16%) 0 4 (16%)
Fluid 4 (16%) 0 4 (16%)
Synovitis 1 (4%) 0 1 (4%)
Hyperemia 0 0 0
Tendon (flexor þ extensor) 0 0 0 0
Tendinosis 0 0 0
Partial thickness tear 0 0 0
Full thickness tear 0 0 0
Joint recess (volar) 3 (12%) 3 (12%) 5 (20%) 12 (48%)
Fluid 3 (12%) 2 (8%) 5 (20%)
Synovitis 1 (4%) 2 (8%) 3 (12%)
Hyperemia 0 0 0
Joint recess (dorsal) 7 (28%) 4 (16%) 11 (44%)
Fluid 1 (4%) 4 (16%) 5 (20%)
Synovitis 5 (20%) 2 (8%) 7 (28%)
Hyperemia 2 (8%) 0 2 (8%)
AI indicates aromatase inhibitor.
a Numbers do not necessarily add up to totals because some patients had >1 abnormality present (eg, both fluid and synovitis of the extensor tendon
sheath).
Table 4. Associations Between Subject Characteristics and Patient-Reported Outcomes and





Baseline Characteristic OR (95% CI) P OR (95% CI) P
Age (<55 y vs 55 y) 0.18 (0.01-3.1) .24 0.23 (0.01-4.2) .32
BMI (<25, 25-30, >30 kg/m2) 0.43 (0.11-1.7) .22 0.16 (0.03-0.84) .03
Prior tamoxifen (no vs yes) 0.21 (0.02-3.1) .26 0.05 (0.002-1.0) .05
Prior chemotherapy (no vs yes) 0.26 (0.04-1.9) .19 0.19 (0.02-1.74) .14
HAQ score 0.59 (0.31-1.1) .11 0.73 (0.38-1.43) .36
VAS score 1.26 (0.77-2.1) .36 0.90 (0.52-1.55) .70
DASH score 1.04 (0.92-1.2) .52 1.09 (0.96-1.25) .17
Change in measurement
(baseline and 3 mo)
HAQ score 1.15 (0.57-2.3) .70 1.39 (0.68-2.88) .37
VAS score 1.56 (0.42-5.8) .51 1.43 (0.46-4.48) .54
DASH score 1.05 (0.91-1.2) .52 1.09 (0.93-1.29) .28
Change in measurement
(baseline and 12 mo)
HAQ score 2.76 (0.3-26.6) .38 6.02 (0.4-83.8) .18
VAS score 2.11 (1.1-4.2) .03 2.12 (1.1-4.1) .02
AIMSS indicates aromatase inhibitor-musculoskeletal symptoms; OR, odds ratio; 95% CI, 95% confidence interval; BMI,
body mass index; HAQ, Health Assessment Questionnaire; VAS, Visual Analog Scale; DASH, Disabilities of the Arm,
Shoulder, and Hand questionnaire.
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treatment discontinuation because of musculoskeletal
symptoms.
A limitation of the current study is the lack of multi-
ple, long-term ultrasound assessments during AI therapy.
Patients were assessed after 3 months of therapy, but the
median time to reported AIMSS in this cohort was
approximately 6 months. Therefore, it is possible that we
were unable to detect a statistically significant association
between ultrasound-detected abnormalities and patient-
reported symptoms because of insufficient time point
assessments. This restriction to analysis of the data from
the 3-month time point may also have led to the lack of a
noted association between changes in the HAQ and VAS
scores and the development of AIMSS or early treatment
discontinuation, which is also supported by our finding of
a statistically significant association between changes in
the VAS score between baseline and 12 months and both
the development of AIMSS and early treatment discontin-
uation. A second limitation of the current study is the rela-
tively small subject cohort, which was further decreased
by early treatment discontinuation by 5 patients, thereby
reducing statistical power.
Another possible limitation is the use of ultrasonog-
raphy as opposed to MRI. One potential criticism of
ultrasonography is operator-dependent variability. In the
current study, we attempted to decrease this variability as
much as possible through the collection and storage of
both static images and cine clips for each subject at each
time point for later analysis by a single, blinded reviewer.
Advantages of high-resolution ultrasound include lower
cost, shorter evaluation time, and a lack of factors that can
preclude assessment with MRI, such as claustrophobia
and the presence of metal in the body.
In summary, the findings of the current pilot study
suggest that the presence of abnormalities of the wrist ten-
don sheath before the initiation of AI therapy may be pre-
dictive of the subsequent development of AIMSS both at
Figure 2. Associations between (Top) the presence of ultra-
sonographic (US) abnormalities at baseline and treatment-
emergent aromatase inhibitor (AI)-associated musculoskel-
etal symptoms (AIMSS) and (Bottom) early treatment dis-
continuation because of musculoskeletal symptoms are
shown. d/c indicates discontinue. All comparisons were found
to nonstatistically significant. *p¼.06.
Figure 3. Associations between (Top) the percentage of new
ultrasonographic (US) abnormalities after 3 months of aro-
matase inhibitor (AI) therapy and treatment-emergent AI-
associated musculoskeletal symptoms (AIMSS) and (Bottom)
early treatment discontinuation because of musculoskeletal
symptoms are shown. d/c indicates discontinue. All compari-
sons were found to be nonstatistically significant.
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the wrist and at other anatomic sites. Future studies are
warranted to confirm the trend noted in this pilot study,
and to further elucidate the predictive role for imaging
when making treatment decisions concerning adjuvant
endocrine therapy.
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